Article
The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).
Atherosclerosis - 1 Jul 2006
Tai E Shyong, Collins Dorothea, Robins Sander J, O'Connor John J, Bloomfield Hanna E, Ordovas Jose M, Schaefer Ernst J, Brousseau Margaret E
Abstract excerpt
BACKGROUND: The Veterans Affairs HDL Intervention Trial (VA-HIT) showed that gemfibrozil, which activates peroxisome proliferator-activator receptor alpha (PPARalpha), significantly reduced the risk of cardiovascular (CV) events in men with low HDL cholesterol (< 40 mg/dl) and established coronary heart disease. Treatment was particularly beneficial in those with insulin resistance (IR) or diabetes mellitus (DM)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.